Filters

Choose one market

Market access pathways by country

Explore how an innovative medicine moves from approval to patient access.

Selected market

Kazakhstan

Registration, regulated maximum price, Kazakhstan National Formulary status, GVFMC/CSHI benefit scope and SK-Pharmacy procurement are separate access gates.

NCEM/NDDA / MOH

MOH / expert organization

Formulary Commission / KNF

MOH / payer

SK-Pharmacy / provider

6 decision nodes14 cited sources

For education only — not regulatory, pricing or legal advice.

About the content and how to use it

Evidence checked through 2026-08-03A pathway is a decision map—not a launch-time promise

Locate the relevant route first

These choices define how to read the branches below. They do not predict a payer or provider decision.

Which registration lane applies?The filing date, certificate type and EAEU reference/recognition role change the regulatory work.

Which public-benefit lane applies?GVFMC, CSHI/OSMS, outpatient and inpatient routes have different populations, budgets and execution.

How will the medicine be acquired?Tender, direct purchase and long-term contract routes create different evidence, timing and supply obligations.

Selected routeKazakhstan nationalGVFMC / GOBMPSingle-distributor tender6 applicable nodes

Authorization-to-patient timeline

See the selected route reach the patient

Updates immediately when a choice changes

Expert evaluationadministrative registration result

Maximum-price registrationKNF/list/procurement economics

KNF evidence assessmentpublic list/formulary decisions

GVFMC / CSHI list and benefit decisionprocurement and claims configurationSelected branch

Single-distributor or institutional procurementaccepted delivery and stockSelected branch

First funded patientEligible patient + capable provider + authorization + product + clean payment

1Current certificate route and State Register checked

2Price, KNF and benefit row separately verified

3Award, delivery and stock confirmed

4Patient eligibility, prescription and copay resolved

Do not collapse these decisions

KNF inclusion is not funded access, and an SK-Pharmacy award is not patient availability. The certificate, price, benefit row, contract, delivery and stock must all be checked.

Decision map

What each local node actually produces

Select a row to inspect legal effect and downstream gates

#Local decision / ownerDecision outputDownstream dependencyEvidence

Node linked to cited dossier sourcesProduct/provider execution still requires live verification

What changed for this route

Kazakhstan nationalThe filing date, certificate type and EAEU reference/recognition role change the regulatory work.
GVFMC / GOBMPGVFMC, CSHI/OSMS, outpatient and inpatient routes have different populations, budgets and execution.
Single-distributor tenderTender, direct purchase and long-term contract routes create different evidence, timing and supply obligations.

Structural differences

National/EAEU registration is a date-sensitive branch, not a permanent one-line sequence.
KNF, funded lists and procurement answer different questions.
Registered maximum price, acquisition price and patient payment are distinct price layers.

Price is a stack

1
Manufacturer/reference evidence
2
Registered maximum price
3
SK-Pharmacy or institutional acquisition price
4
Public reimbursement and patient copay

Lifecycle triggers

National/EAEU certificate conversion and variation
Maximum-price update
KNF and benefit-list revision
Procurement renewal, competition and shortage

Special mechanisms and lifecycle

What can reopen price, coverage or procurement after launch

Dates below come from the cited policy record—not a product forecast

Mechanism / triggerDecision outputIteration / branchPolicy recordLatest observed

First funded patient and lifecycle controldispensing/administration and paid public claimcopay, exception, renewal, shortage, repricingKZ-S07 · KZ-S08 · KZ-S13 · KZ-S14current

National/EAEU certificate conversion and variationMaximum-price updateKNF and benefit-list revisionProcurement renewal, competition and shortage

Evidence & policy library

Official basis and policy dates

14 records · checked 2026-08-03